Evercore ISI added West Pharmaceutical (WST) to the firm’s “Tactical Outperform” list, telling investors that Q2 marked an inflection point. Destocking is over and West is well-positioned into 2026, argues the analyst, who believes the growth algorithm should come back. The firm has an Outperform rating and $350 price target on West shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical price target raised to $275 from $260 at Barclays
- Strong Market Position and Growth Potential Justify Buy Rating for West Pharmaceutical Services
- West Pharmaceutical initiated with a Buy at Rothschild & Co Redburn
- West Pharmaceutical Announces Departure of Senior VP
- AI Analyst Is Bullish on These 3 “Strong Buy” Healthcare Stocks, 9/2/25